Orthobiologics was Xtant Medical Holdings’s largest product and service line in fiscal 2024, bringing in $66.42M of $117.27M (57%).
| Product and Service | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 |
|---|---|---|---|---|---|---|---|
| Orthobiologics | $42.26M | $47.14M | $58.61M | $66.42M | |||
| Spinal Implant | $12.89M | $10.83M | $32.70M | $49.35M | |||
| License Revenue | — | — | — | $1.50M | |||
| Other Revenue | $117.00K | — | — | — | |||
| Total | $55.26M | $57.97M | $91.30M | $117.27M |
Xtant Medical Holdings brought in $117.27M from its three product and service lines in fiscal 2024, the year ended December 31, 2024. Xtant Medical Holdings regrouped these lines after fiscal 2023, so the total does not compare directly with that year's $91.30M. Orthobiologics was the largest at $66.42M (56.6%), ahead of Spinal Implant at $49.35M (42.1%) and License Revenue at $1.50M (1.3%).
Compared with fiscal 2023, Spinal Implant grew 50.9% to $49.35M and Orthobiologics grew 13.3% to $66.42M.
Xtant Medical Holdings began breaking out License Revenue in fiscal 2024, when it brought in $1.50M. Xtant Medical Holdings stopped reporting Other Revenue as a separate line after fiscal 2021, when it brought in $117.00K.
United States was Xtant Medical Holdings’s largest region in fiscal 2024, bringing in $105.52M of $117.27M (90%).
| Geography | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $54.57M | $57.16M | $85.86M | $105.52M | |||||||
| Us | — | — | — | — | |||||||
| Non-Us | — | — | — | $11.75M | |||||||
| Rest Of World | $693.00K | $807.00K | $5.44M | — | |||||||
| Total | $55.26M | $57.97M | $91.30M | $117.27M |
Xtant Medical Holdings brought in $117.27M from its two regions in fiscal 2024, the year ended December 31, 2024. Xtant Medical Holdings regrouped these regions after fiscal 2023, so the total does not compare directly with that year's $91.30M. United States was the largest at $105.52M (90.0%), ahead of Non-Us at $11.75M (10.0%).
Xtant Medical Holdings began breaking out Non-Us in fiscal 2024, when it brought in $11.75M. Xtant Medical Holdings stopped reporting Rest Of World as a separate region after fiscal 2023, when it brought in $5.44M.
Us was Xtant Medical Holdings’s largest region in fiscal 2013, bringing in $32.46M of $33.04M (98%).
| Geography | FY 2011 | FY 2012 | FY 2013 |
|---|---|---|---|
| Us | — | $31.95M | $32.46M |
| United States | $29.57M | — | — |
| Rest Of World | $578.04K | $1.03M | $584.59K |
| Total | $30.15M | $32.98M | $33.04M |
Xtant Medical Holdings brought in $33.04M from its two regions in fiscal 2013, the year ended December 31, 2013. That was up 0.2% from $32.98M in fiscal 2012. Us was the largest at $32.46M (98.2%), ahead of Rest Of World at $584.59K (1.8%).
Xtant Medical Holdings began breaking out Us in fiscal 2012, when it brought in $31.95M. Xtant Medical Holdings stopped reporting United States as a separate region after fiscal 2011, when it brought in $29.57M.
Xtant Medical Holdings (XTNT) reports its revenue by product and service and by geography. In fiscal 2024, Orthobiologics was its largest product and service line, bringing in $66.42M (56.6% of the total), followed by Spinal Implant at $49.35M (42.1%).
Orthobiologics was Xtant Medical Holdings' largest product and service line in fiscal 2024, bringing in $66.42M, or 56.6% of the $117.27M total across its three product and service lines.
United States was Xtant Medical Holdings' largest region in fiscal 2024, bringing in $105.52M, or 90.0% of the $117.27M total across its two regions.
Every figure comes from Xtant Medical Holdings' annual financial filings, as reported. Each line keeps the name Xtant Medical Holdings gives it, and years follow its fiscal calendar.
Xtant Medical Holdings' revenue by product and service goes back to fiscal 2018, with figures through fiscal 2024. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.